Effect of hydroxyethyl starch 130/0.4 and 200/0.5 solutions on canine platelet function in vitro

American Journal of Veterinary Research

Volumn 74, Issue 8, 2013, Pages 1133-1137

  McBride, Duana ^a   Hosgood, Giselle L ^a   Mansfield, Caroline S ^b   Smart, Lisa ^a  

^a MURDOCH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; DOG; ERROR; FEMALE; MALE; NONHUMAN; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER;

ANIMALS; BLOOD PLATELETS; DOGS; FEMALE; HETASTARCH; MALE; PLATELET AGGREGATION;

EID: 84880652568     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.8.1133     Document Type: Article

References (36)

1. Raja SG, Akhtar S, Shahbaz Y, et al. In cardiac surgery patients does Voluven(R) impair coagulation less than other colloids? Interact Cardiovasc Thorac Surg 2011;12:1022-1027.
2. Sossdorf M, Marx S, Schaarschmidt B, et al. HES 130/0.4 impairs haemostasis and stimulates pro-inflammatory blood platelet function. Crit Care [serial online]. 2009;13:R208. Available at: ccforum.com/content/13/6/R208. Accessed June 6, 2011.
3. Matsota P, Politou M, Kalimeris K, et al. Do different substi-tution patterns or plant origin in hydroxyethyl starches af-fect blood coagulation in vitro? Blood Coagul Fibrinolysis 2010;21:448-451.
4. Liu FC, Liao CH, Chang YW, et al. Hydroxyethyl starch inter-feres with human blood ex vivo coagulation, platelet function and sedimentation. Acta Anaesthesiol Taiwan 2009;47:71-78.
5. Scharbert G, Deusch E, Kress HG, et al. Inhibition of plate-let function by hydroxyethyl starch solutions in chronic pain patients undergoing peridural anesthesia. Anesth Analg 2004;99:823-827.
6. Wierenga JR, Jandrey KE, Haskins SC, et al. In vitro comparison of the effects of two forms of hydroxyethyl starch solutions on platelet function in dogs. Am J Vet Res 2007;68:605-609.
7. Smart L, Jandrey KE, Kass PH, et al. The effect of hetastarch (670/0.75) in vivo on platelet closure time in the dog. J Vet Emerg Crit Care (San Antonio) 2009;19:444-449.
8. Chohan AS, Greene SA, Grubb TL, et al. Effects of 6% heta-starch (600/0.75) or lactated Ringer's solution on hemostatic variables and clinical bleeding in healthy dogs anesthetized for orthopedic surgery. Vet Anaesth Analg 2011;38:94-105.
9. Gandhi SD, Weiskopf RB, Jungheinrich C, et al. Volume replace-ment therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology 2007;106:1120-1127.
10. Kasper SM, Meinert P, Kampe S, et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion re-quirements in coronary artery bypass surgery compared withhydroxyethyl starch 200/0.5 at recommended doses. Anesthesi-ology 2003;99:42-47.
11. Schramko AA, Suojaranta-Ylinen RT, Kuitunen AH, et al. Rap-idly degradable hydroxyethyl starch solutions impair blood co-agulation after cardiac surgery: a prospective randomized trial. Anesth Analg 2009;108:30-36.
12. Schramko AA, Suojaranta-Ylinen RT, Kuitunen AH, et al. Com-parison of the effect of 6% hydroxyethyl starch and gelatine on cardiac and stroke volume index: a randomized, controlled trial after cardiac surgery. Perfusion 2010;25:283-291.
13. Hayward CP, Harrison P, Cattaneo M, et al. Platelet function ana-lyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319.
14. Callan MB, Giger U. Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs. Am J Vet Res 2001;62:652-658.
15. Keidel A, Mischke R. Clinical evaluation of platelet function analyzer PFA-100 in dogs [in German]. Berl Munch Tierarztl Wochenschr 1998;111:452-456.
16. Mischke R, Keidel A. Influence of platelet count, acetylsalicylic acid, von Willebrand's disease, coagulopathies, and haematocrit on results obtained using a platelet function analyser in dogs. Vet J 2003;165:43-52.
17. Liang H, Yang CX, Li H, et al. The effects of preloading in-fusion with hydroxyethyl starch 200/0.5 or 130/0.4 solu-tion on hypercoagulability and excessive platelet activation of patients with colon cancer. Blood Coagul Fibrinolysis 2010;21:406-413.
18. Franz A, Braunlich P, Gamsjager T, et al. The effects of hydroxy-ethyl starches of varying molecular weights on platelet function. Anesth Analg 2001;92:1402-1407.
19. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, et al. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg 2008;107:382-390.
20. Navickis RJ, Haynes GR, Wilkes MM. Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analy-sis of randomized trials. J Thorac Cardiovasc Surg 2012;144:223-230.
21. Gattas DJ, Dan A, Myburgh J, et al. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg 2012;114:159-169.
22. Classen J, Adamik KN, Weber K, et al. In vitro effect of hydroxy-ethyl starch 130/0.42 on canine platelet function. Am J Vet Res 2012;73:1908-1912.
23. Turitto VT, Baumgartner HR. Platelet interaction with sub-endothelium in flowing rabbit blood: effect of blood shear rate. Microvasc Res 1979;17:38-54.
24. Alkhamis TM, Beissinger RL, Chediak JR. Artificial surface ef-fect on red blood cells and platelets in laminar shear flow. Blood 1990;75:1568-1575.
25. Fenger-Eriksen C, Tonnesen E, Ingerslev J, et al. Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. J Thromb Haemost 2009;7:1099-1105.
26. de Jonge E, Levi M, Buller HR, et al. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med 2001;27:1825-1829.
27. Jamnicki M, Bombeli T, Seifert B, et al. Low-and medium-molecular-weight hydroxyethyl starches: comparison of their effect on blood coagulation. Anesthesiology 2000;93:1231-1237.
28. Deusch E, Gamsjager T, Kress HG, et al. Binding of hydroxy-ethyl starch molecules to the platelet surface. Anesth Analg 2003;97:680-683.
29. Kozek-Langenecker SA. Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology 2005;103:654-660.
30. Treib J, Baron JF, Grauer MT, et al. An international view of hy-droxyethyl starches. Intensive Care Med 1999;25:258-268.
31. von Roten I, Madjdpour C, Frascarolo P, et al. Molar substitu-tion and C2/C6 ratio of hydroxyethyl starch: influence on blood coagulation. Br J Anaesth 2006;96:455-463.
32. Lamke LO, Liljedahl SO. Plasma volume changes after infusion of various plasma expanders. Resuscitation 1976;5:93-102.
33. Waitzinger J, Bepperling F, Pabst G, et al. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs R D 2003;4:149-157.
34. Winterhalter M, Malinski P, Danzeisen O, et al. Prospective ob-servational study for perioperative volume replacement with 6% HES 130/0, 42, 4% gelatin+6 and 6% HES 200/0, 5 in cardiac surgery. Eur J Med Res 2010;15:383-389.
35. Reinhart K, Perner A, Sprung CL, et al. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med 2012;38:368-383.
36. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis cam-paign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.